




Heart failure is the pathophysiological state charac-
terized by ventricular dysfunction and associated clinical
symptoms. It is a major cause of cardiovascular mortality
and morbidity
1). Decreased systolic or diastolic cardiac
function results in abnormal circulatory hemodynamics, ac-
tivation of a variety of neurohormonal systems and re-
tention of sodium and water
2). The integrity of the arterial
circulation is determined by cardiac output and peripheral
vascular resistance. Decrease in cardiac output or periph-
eral arterial vasodilatation causes arterial underfilling. That
is an important signal which triggers multiple neuro-
hormonal systems to maintain adequate arterial pressure
and peripheral perfusion of the vital organs
3). The kidney
is the principal organ affected when cardiac output de-
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clines. The kidney plays an important role in the main-
tenance of body fluid volume which is regulated by multi-
ple neurohormonal systems. Alterations of hemodynamics
and neurohormonal systems in heart failure result in renal
sodium and water retention
4). This review discusses the
pathophysiologic mechanisms of sodium and water re-
tention in heart failure.
Activation of neurohormonal systems
In heart failure, the sympathetic nervous system (SNS)
is activated. It has been demonstrated by an increase in
plasma concentrations of catecholamine in patients with
heart failure
5, 6). Increased catecholamine secretion plays
a role in the maintenance of blood pressure in heart failure.
In addition, activation of SNS contributes to renal sodium
and water retention in heart failure. In the kidney, SNS
plays a stimulatory role in renal tubular reabsorption of
sodium and water
7). Previous studies have demonstrated
a direct effect of renal nerve activation on renal sodium
and water reabsorption across the proximal tubular
epithelium. Adrenergic innervations in the basement mem-
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brane of renal tubular epithelial cells were demonstrated
8,
9). Low-frequency electrical stimulation of the renal nerves
resulted in an antidiuretic and antinatriuretic response in
the absence of changes in glomerular filtration rate (GFR)
or renal plasma flow
8). Moreover, the protein expression
of aquaporin (AQP) water channels was decreased in the
denervated kidney
10). Renal denervation decreased sodium
and water retention in experimental heart failure
11). In addi-
tion, the activation of renal nerves stimulates the re-
nin-angiotensin-aldosterone system (RAAS) by stimulating
renin release
3, 12).
In heart failure, the RAAS is stimulated. Plasma renin
activity, angiotensin II and aldosterone concentrations are
increased
13). Angiotensin II is an important mediator of so-
dium and water retention in patients with heart failure.
Angiotensin II directly enhances proximal tubular re-
absorption of sodium and water
14). Angiotensin II receptor
blocker treatment resulted in natriuresis in experimental
heart failure
15). In addition, it was demonstrated that aldos-
terone antagonist spironolactone increased urinary sodium
excretion in patients with heart failure
16).
In the kidney, natriuretic peptides (NPs) increase the
GFR and urinary sodium excretion by afferent arteriolar
vasodilation and efferent arteriolar constriction
17). More-
over, NPs inhibit sodium and water reabsorption induced
by angiotensin II action in the proximal tubule and they
directly inhibit sodium reabsorption in the collecting duct
18,
19). NPs also inhibit renin release and aldosterone syn-
thesis
20). The NPs are increased in heart failure
21, 22).
However, the renal responses of NPs were blunted in pa-
tients with heart failure
23). The resistance may be due to
down-regulation of renal NP receptors, secretion of in-
active immunoreactive NPs, increased degradation of NPs
by neutral endopeptidase in the proximal tubule or de-
creased sodium delivery to the collecting duct as a result
of increased sodium reabsorption in the proximal tubule
3).
Arginine vasopressin (AVP) is an antidiuretic hormone
which is synthesized in the hypothalamus, stored in the
posterior pituitary gland and released in response to in-
creased osmolality or volume depletion. In the kidney,
AVP causes antidiuresis by activating vasopressin V2 re-
ceptors on the basolateral membrane of the principal cells
in the collecting duct. This process results in passive water
reabsorption along the osmotic gradient. In heart failure,
AVP secretion occurs despite a normal or even low plasma
osmolality (non-osmotic AVP release)
24). Arterial under-
filling in heart failure contributes to the breakdown of bar-
oreceptor-mediated suppression of AVP. In addition, an-
giotensin II stimulates the release of AVP by the stim-
ulation of the thirst center of the brain
3, 12). Thus, the dysre-
gulation of AVP plays an important role in the develop-
ment of hypoosmolar hyponatremia in patients with heart
failure.
Dysregulation of AQP and sodium transporters
In the kidney, AQP water channels allow the movement
of water across the tubular epithelium. AQP1 is abundant
in the proximal tubule and descending thin limb and is
essential for urinary concentration
25). AQP2 is exclusively
expressed in the principal cells of the connecting tubule
and collecting duct
26). It is regulated in the short-term and
long-term by the AVP/Cyclic adenosine monophosphate
(cAMP) pathway to increase osmotic water reabsorption
27,
28). AQP3 is present in the basolateral membranes of col-
lecting duct principal cells and represents exit pathways
of water reabsorbed via AQP2 in the apical membranes
29).
In experimental heart failure, up-regulation of AQP2 has
been documented. Nielsen et al. reported increased ex-
pression and targeting of AQP2 in association with hypo-
natremia in experimental heart failure
30). Xu et al. also
demonstrated up-regulation of AQP2 in chronic heart fail-
ure rats
31). In this study, the expression of AQP2 massenger
RNA and protein was increased in associated to increased
plasma AVP levels in heart failure rats. V2 receptor antag-
onist treatment induced a significant diuresis, decrease in
urinary osmolality and increase in plasma osmolality in
heart failure rats. Up regulation of AQP2 in heart failure
is inhibited by the treatment of V2 receptor antagonist.
Moreover, it was demonstrated that V2 receptor antago-
nism decreases urinary AQP2 excretion in patients with
chronic heart failure
32). These results suggest that upregula-
tion of vasopressin and AQP2 plays an important role in40 Electrolyte Blood Press 7:38-41, 2009
the development of water retention and hyponatremia in
heart failure.
The renal sodium transporters play a critical role in the
sodium reabsorption and regulation of extracellular fluid
volume. The renal tubular sodium reabsorption is basically
linked to the activity of Na
+,K
+-ATPase that is heavily ex-
pressed in the basolateral membrane throughout the neph-
ron segments
33). The proximal tubule reabsorbs approx-
imately two-thirds of the filtered sodium load. In this seg-
ment, type 3 Na
+/H
+ exchanger (NHE3) is mainly respon-





- cotransporter (NKCC2) is localized
at the apical membrane of the thick ascending limb and
mediates the apical NaCl transport in this water im-
permeable segment
35). In the distal convoluted tubule, the
thiazide-sensitive Na
+/Cl
- cotransporter (NCC) is involved
in the apical movement of sodium
36). On the other hand,
epithelial sodium channel (ENaC) is expressed in the con-
necting tubule and collecting duct
37).
Recently, altered regulations of renal sodium trans-
porters in heart failure have been documented. Torp et al.
demonstrated that the expression of NKCC2 was increased
in heart failure rats. This change was decreased by losartan
treatment. In addition, heart failure rats had increased basal
and AVP stimulated cAMP accumulation in the thick as-
cending limb, which was abolished by losartan treatment
38).
These results may suggest that up-regulation of NKCC2
in heart failure rats plays a role in the increased sodium
reabsorption in the thick ascending limb. The NKCC2 ex-
pression may be regulated by an interaction between V2
receptor and angiotensin II receptor. In addition, it was
demonstrated that the expressions of AQP2, NHE3,
NKCC2 and -ENaC were increased in heart failure rats, α
which were reversed or prevented by candersartan treat-
ment
39). These findings suggest that angiotensin II and the
dysregulation of AQP2 and sodium transporters plays an
important role in the pathogenesis of renal sodium and wa-
ter retention in heart failure.
Conclusions
In heart failure, activation of SNS, RAAS, resistance
to NPs and non-osmotic vasopressin release stimulate the
renal tubular reabsorption of sodium and water. Dysregula-
tion of AQP2 and sodium transporters also play an im-
portant role in the pathogenesis of renal sodium and water
retention.
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